Eric Tichy

1 month ago | managedhealthcareexecutive.com | Eric Tichy

March 7, 2025By A panelist discusses how managing biosimilars requires close collaboration between payers and health systems to optimize patient care and cost savings, while sharing insights about program implementation challenges across different care settings and emphasizing the importance of robust operational frameworks. Video content above is prompted by the following: What would you like your payer colleagues to know about the use of biosimilars in the health system?

1 month ago | managedhealthcareexecutive.com | Eric Tichy

February 28, 2025By A panelist discusses how their institution is proactively adapting their formulary review processes and infrastructure to handle the growing biosimilar pipeline, while anticipating increased competition will drive strategic shifts in contracting and necessitate more flexible approaches to formulary management in the coming years. Video content above is prompted by the following: How are you preparing for the increasing number of biosimilars entering the market?

2 months ago | managedhealthcareexecutive.com | Eric Tichy

February 21, 2025By A panelist discusses how their institution implements robust safety protocols including distinct labeling, electronic health record alerts, and staff education to prevent dispensing errors when managing multiple biosimilars, while also conducting targeted educational outreach to address stakeholder concerns about interchangeability.

2 months ago | drugtopics.com | Brian Nowosielski |Eric Tichy

Health-system pharmacy has seen impactful growth in the recent past. However, as market pressures and regulatory framework create barriers in a unique health care landscape, the business of keeping health systems sustainable has become a unique challenge for pharmacists and other health-system providers. “Health-system pharmacy has grown alongside the rapid growth of specialty pharmacy.

2 months ago | managedhealthcareexecutive.com | Eric Tichy

February 14, 2025By A panelist discusses how payer contract requirements and reimbursement policies significantly influence their institution’s biosimilar adoption strategy, requiring careful analysis of net cost benefits when weighing potential savings against the operational complexities of managing multiple products. Video content above is prompted by the following: How do payer contracts and reimbursement policies influence your biosimilar adoption decisions?